AstraZeneca to pay up to $2 billion to license cardiovascular drug

AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.

Previous post Now a billionaire, here’s where Selena Gomez puts her real estate money
Next post China’s rally still has ‘more legs,’ Goldman Sachs says